Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Cancer Immunol Immunother
2005 May 01;545:446-52. doi: 10.1007/s00262-004-0619-4.
Show Gene links
Show Anatomy links
Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC
,
Zou LY
,
Ni B
,
Wan Y
,
Zhou W
,
Lv YB
,
Geng M
,
Wu YZ
.
???displayArticle.abstract???
Plasmid DNA vaccine is an appealing cancer immunotherapy. However, it is a weak immunogen and immunization with plasmid DNA encoding self-antigens, such as melanoma-associated antigens, could not induce antitumor immunity because of tolerance. In this study, we investigated the feasibility of using a plasmid DNA encoding Xenopus laevis transforming growth factor-beta 5 (aTGF-beta5) as an immunogen to induce neutralizing antibodies against murine TGF-beta1 (mTGF-beta1) and thus enhance the efficacy of plasmid DNA vaccine encoding murine tyrosinase-related protein 2 (mTRP-2) through neutralization of TGF-beta. The results showed that immunization with aTGF-beta5 resulted in the generation of mTGF-beta1-neutralizing antibodies, and immunization with a combination of aTGF-beta5 and mTRP-2 induced specific cytotoxic T lymphocytes (CTLs). On the contrary, immunization with mTRP-2 alone could not elicit the CTL response. Moreover, immunization of C57BL/6 wild-type mice with a combination of aTGF-beta5 and mTRP-2 induced the protective and therapeutic antitumor immunity to B16F10 melanoma, whereas the antitumor activity was abrogated in both CD4-deficient mice and CD8-deficient mice on the C57BL/6 background. Our results indicate that immunization with aTGF-beta5 is capable of breaking immune tolerance and induces mTGF-beta1-neutralizing antibodies. Neutralization of TGF-beta can enhance the efficacy of DNA vaccine encoding mTRP-2 and the induction of antitumor immunity by this immunization strategy is associated with CD4+ and CD8+ T cells.
Bloom,
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
1997, Pubmed
Bloom,
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
1997,
Pubmed
Bowne,
Coupling and uncoupling of tumor immunity and autoimmunity.
1999,
Pubmed
Brichard,
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
1993,
Pubmed
Brunner,
Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins.
1989,
Pubmed
Derynck,
The murine transforming growth factor-beta precursor.
1986,
Pubmed
Gold,
The role for transforming growth factor-beta (TGF-beta) in human cancer.
1999,
Pubmed
Gorelik,
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
2001,
Pubmed
Gorelik,
Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.
2000,
Pubmed
Gorelik,
Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation.
2002,
Pubmed
Gurunathan,
DNA vaccines: immunology, application, and optimization*.
2000,
Pubmed
Harada,
Characterization of B16 melanoma-specific cytotoxic T lymphocytes.
1998,
Pubmed
Kobie,
Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
2003,
Pubmed
Kondaiah,
Identification of a novel transforming growth factor-beta (TGF-beta 5) mRNA in Xenopus laevis.
1990,
Pubmed
,
Xenbase
Kong,
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.
1995,
Pubmed
Maeda,
TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.
1996,
Pubmed
Mendiratta,
Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
2001,
Pubmed
Miconnet,
Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
2001,
Pubmed
Morelli,
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation.
2001,
Pubmed
Okada,
Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
2003,
Pubmed
Pardoll,
Inducing autoimmune disease to treat cancer.
1999,
Pubmed
Perricone,
Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens.
2000,
Pubmed
Piechocki,
Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
2001,
Pubmed
Romagnani,
The Th1/Th2 paradigm.
1997,
Pubmed
Rosenberg,
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
1996,
Pubmed
Schwartz,
T cell clonal anergy.
1997,
Pubmed
Steitz,
Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma.
2000,
Pubmed
Steitz,
Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.
2002,
Pubmed
Su,
Transforming growth factor-beta expression and natural killer cell responses during virus infection of normal, nude, and SCID mice.
1993,
Pubmed
Svane,
The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.
1999,
Pubmed
Topalian,
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
1994,
Pubmed
van der Bruggen,
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
1991,
Pubmed
van Elsas,
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
2001,
Pubmed
Wang,
The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
2001,
Pubmed
Wang,
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.
1996,
Pubmed
Weber,
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
1998,
Pubmed
Wei,
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
2001,
Pubmed
,
Xenbase
